SCHEMBL5135259

SCHEMBL5135259

CCCCn1c(CN(Cc2ccccc2)Cc2c(F)c(F)cc(F)c2F)cnc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.41
KDM4E B2RXH2 4/20 0.37
HSD11B1 P28845 2/20 0.36
C5AR1 P21730 1/20 0.35
HSD17B10 Q99714 2/20 0.34
PDE4B Q07343 2/20 0.33
NR1H3 Q13133 1/20 0.33
ADORA2B P29275 1/20 0.32
HTT P42858 3/20 0.32
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 2/20 0.32
MAPK1 P28482 1/20 0.32
GRIN2B Q13224 1/20 0.31
CRHR1 P34998 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072278 0.88 TSHR (0.51) TSHRKDM4EHSD11B1C5AR1HSD17B10
SCHEMBL5135909 0.87 C5AR1 (0.53) TSHRC5AR1ALDH1A1SMN1; SMN2LMNA
SCHEMBL14415591 0.87 HTT (0.43) TSHRKDM4EHSD11B1C5AR1HSD17B10
SCHEMBL5134992 0.86 TSHR (0.41) TSHRKDM4EHSD11B1C5AR1HSD17B10
SCHEMBL5074850 0.86 TSHR (0.42) TSHRKDM4EHSD11B1C5AR1HSD17B10
SCHEMBL5136523 0.85 KDM4E (0.42) TSHRKDM4EHSD11B1NR1H3HTT
SCHEMBL5137471 0.85 TSHR (0.40) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5135136 0.85 TSHR (0.40) TSHRKDM4EHSD11B1C5AR1HSD17B10
SCHEMBL5136036 0.84 TSHR (0.45) TSHRKDM4EHSD11B1C5AR1HSD17B10
SCHEMBL5137319 0.84 TSHR (0.47) TSHRKDM4EHSD11B1C5AR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed